BiotechTube
Home/Geron/Andrew J. Grethlein, Ph.D.
AJ

Andrew J. Grethlein, Ph.D.

Executive Vice President and Chief Operating Officer

Geron

Therapeutic Areas

Hematologic MalignanciesMyeloid Cancers

Geron Pipeline

DrugIndicationPhase
Imetelstat (Rytelo™)Transfusion-Dependent Anemia in Lower-Risk Myelodysplastic Syndromes (MDS)Approved
ImetelstatJAK Inhibitor Relapsed/Refractory Myelofibrosis (MF)Phase 3
Imetelstat + RuxolitinibFrontline Myelofibrosis (MF)Phase 1
Imetelstat + Azacitidine ± VenetoclaxRelapsed/Refractory Acute Myeloid Leukemia (R/R AML)Phase 1

Leadership Team at Geron

JA
John A. Scarlett, M.D.
Chief Executive Officer and Chairman
FF
Faye Feller, M.D.
Executive Vice President and Chief Medical Officer
MR
Michelle Robertson
Executive Vice President and Chief Financial Officer
AK
Anil Kapur
Executive Vice President, Corporate Strategy and Chief Commercial Officer
View full Geron profile